{
    "nct_id": "NCT01409915",
    "title": "Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine\u00ae) in the Treatment of Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-05-12",
    "description_brief": "A medicine that is FDA-approved for bone marrow stimulation (called Leukine) will be tested for its ability to be tolerated by Alzheimer's disease patients and potentially to improve their memory.",
    "description_detailed": "Preliminary preclinical results demonstrated that GM-CSF (Granulocyte macrophage colony-stimulating factor, e.g. Leukine\u00ae/Sargramostim) rapidly reduced cerebral amyloid deposition and completely reversed memory deficits in transgenic mouse models of Alzheimer's Disease (AD). To assess the efficacy of GM-CSF in humans, the investigators performed a retrospective analysis of a cognition study of human patients undergoing hematopoietic cell transplantation for cancer and who garner cognitive impairments from the chemotherapy or irradiation. In the patients that received a colony-stimulating factor (CSF) to stimulate the bone marrow and recover immune system function, the investigators found that those who received GM-CSF (Leukine\u00ae/Sargramostim) plus G-CSF (Filigrastim) significantly improved in cognitive function as compared to those who received G-CSF alone. These findings combined with over two decades of accrued safety data using recombinant human GM-CSF, Leukine\u00ae/Sargramostim, in elderly leukopenic patients, suggested that Leukine\u00ae should be tested as a treatment to reverse cerebral amyloid pathology and cognitive impairment in AD.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Sagramostim (Leukine)",
                    "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                },
                {
                    "id": "FG001",
                    "title": "Control Group",
                    "description": "Saline placebo comparator: subcutaneous injection"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "23"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "20"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "20"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "The analysis population is Per Protocol, with all participants enrolled and randomized in the clinical trial, and who complete the treatment without major breaches in the study protocol.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "Sagramostim (Leukine)",
                    "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                },
                {
                    "id": "BG001",
                    "title": "Control Group",
                    "description": "Saline placebo comparator: subcutaneous injection"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "20"
                        },
                        {
                            "groupId": "BG001",
                            "value": "20"
                        },
                        {
                            "groupId": "BG002",
                            "value": "40"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "Years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "67.10",
                                            "spread": "6.57"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "70.15",
                                            "spread": "6.42"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "68.63",
                                            "spread": "6.59"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "23"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "17"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race/Ethnicity, Customized",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "Race / Ethnicity",
                            "categories": [
                                {
                                    "title": "White / Caucasian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "39"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black / African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian / Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Hispanic / Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Other",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "40"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Education Level (Mean years)",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "Years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "15.70",
                                            "spread": "2.92"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "15.80",
                                            "spread": "2.71"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "15.75",
                                            "spread": "2.78"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Adverse Events (AEs) by Body System",
                    "description": "Count of AE's from Consent to Follow-up 2 within a safety analysis set consisting of all participants who were enrolled and randomized and who received at least one injection of sargramostim or placebo",
                    "populationDescription": "Safety analysis set (SAS), all participants enrolled and randomized and who received at least one injection of sargramostim or placebo",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Adverse Events",
                    "timeFrame": "20 weeks (From Consent to Follow-up 2)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sagramostim (Leukine)",
                            "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Control Group",
                            "description": "Saline placebo comparator: subcutaneous injection"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Cardiovascular AE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Constitutional",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Dental",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Dermatological",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "ENT",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Gastrointestinal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Musculoskeletal",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "11"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Neurological",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Psychological",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Respiratory",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "MMSE (Mini Mental State Examination) From Baseline to End of Treatment (3 Weeks), Follow-Up 1 (45 Days Post Treatment) and Follow-Up 2 (90 Days Post Treatment)",
                    "description": "Mini-Mental State Examination (MMSE) is a brief psychometric instrument developed to assess cognitive function in elderly populations. It is a standard assessment used by all NIH Alzheimer's Disease Centers (ADCCs and ADRCs) to identify and monitor individuals with AD. The range for scores in the MMSE is from 0 to 30, with lower scores indicating greater impairment.",
                    "populationDescription": "The analysis population is Per Protocol, with all participants enrolled and randomized in the clinical trial, and who complete the treatment without major breaches in the study protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "From Baseline to End of Treatment (3 weeks), Follow-Up 1 (45 days post treatment) and Follow-Up 2 (90 days post treatment)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sagramostim (Leukine)",
                            "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Control Group",
                            "description": "Saline placebo comparator: subcutaneous injection"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "20"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.10",
                                            "spread": "4.57"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20.75",
                                            "spread": "4.97"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "End of Treatment (3 weeks)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18.55",
                                            "spread": "4.99"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20.40",
                                            "spread": "5.28"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 1 (45 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18.00",
                                            "spread": "5.52"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "19.90",
                                            "spread": "5.19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 2 (90 days pot treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.10",
                                            "spread": "5.78"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "19.40",
                                            "spread": "5.47"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) From Baseline to End of Treatment (3 Weeks), Follow-Up 1 (45 Days Post Treatment) and Follow-Up 2 (90 Days Post Treatment)",
                    "description": "Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-Cog13). The ADAS-Cog13 is the most popular cognitive testing instrument used in clinical trials of nootropics (drugs or agents that improve cognitive function). It consists of 13 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities, which are often referred to as the core symptoms of AD. Score ranges from 0-85, with a higher score representing more severe impairment",
                    "populationDescription": "The analysis population is Per Protocol, with all participants enrolled and randomized in the clinical trial, and who complete the treatment without major breaches in the study protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline to End of Treatment (3 weeks), Follow-Up 1 (45 days post treatment) and Follow-Up 2 (90 days post treatment)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sagramostim (Leukine)",
                            "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Control Group",
                            "description": "Saline placebo comparator: subcutaneous injection"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "20"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "43.20",
                                            "spread": "12.45"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "36.20",
                                            "spread": "12.01"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "End of Treatment (3 weeks)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "43.54",
                                            "spread": "12.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "36.68",
                                            "spread": "11.63"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 1 (45 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "47.67",
                                            "spread": "11.89"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "36.33",
                                            "spread": "9.85"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 2 (90 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "45.87",
                                            "spread": "13.21"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "36.85",
                                            "spread": "10.24"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "OTHER_PRE_SPECIFIED",
                    "title": "Alzheimer's Disease Cooperative Study -Activities of Daily Living Inventory (ADCS-ADL) From Baseline to End of Treatment (3 Weeks), Follow-Up 1 (45 Days Post Treatment) and Follow-Up 2 (90 Days Post Treatment)",
                    "description": "The ADCS-ADL is a caregiver/study partner rated questionnaire of 23 items, with possible scores over a range of 0-78, where 78 implies full functioning with no impairment. The ADCS-ADL assesses functional capacity across a wide spectrum of severity",
                    "populationDescription": "The analysis population is Per Protocol, with all participants enrolled and randomized in the clinical trial, and who complete the treatment without major breaches in the study protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline to End of Treatment (3 weeks), Follow-Up 1 (45 days post treatment) and Follow-Up 2 (90 days post treatment)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sagramostim (Leukine)",
                            "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Control Group",
                            "description": "Saline placebo comparator: subcutaneous injection"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "20"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "56.50",
                                            "spread": "12.30"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "62.75",
                                            "spread": "8.98"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "End of Treatment (3 weeks)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "57.00",
                                            "spread": "11.93"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "61.85",
                                            "spread": "9.32"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 1 (45 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "53.35",
                                            "spread": "14.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "59.85",
                                            "spread": "9.05"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 2 (90 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "53.30",
                                            "spread": "15.00"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "60.30",
                                            "spread": "9.00"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "OTHER_PRE_SPECIFIED",
                    "title": "Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) From Baseline to End of Treatment (3 Weeks), Follow-Up 1 (45 Days Post Treatment) and Follow-Up 2 (90 Days Post Treatment)",
                    "description": "The CDR is a study partner/caregiver and participant based interview to assess changes in domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated as 0 (no dementia), 0.5 (uncertain dementia), 1 (mild dementia), 2 (moderate dementia), or 3 (severe dementia). The Sum of Boxes score (CDR-SB) score was tallied for each administration using the rules from the Washington University Knight ADRD scoring algorithm. Scores range from 0-18. The higher the score, the worse the impairment.",
                    "populationDescription": "The analysis population is Per Protocol, with all participants enrolled and randomized in the clinical trial, and who complete the treatment without major breaches in the study protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline to End of Treatment (3 weeks), Follow-Up 1 (45 days post treatment) and Follow-Up 2 (90 days post treatment)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sagramostim (Leukine)",
                            "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Control Group",
                            "description": "Saline placebo comparator: subcutaneous injection"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "20"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.10",
                                            "spread": "3.32"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6.10",
                                            "spread": "2.67"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "End of Treatment (3 weeks)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.53",
                                            "spread": "3.37"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5.95",
                                            "spread": "2.37"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 1 (45 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.42",
                                            "spread": "4.22"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6.81",
                                            "spread": "3.12"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 2 (90 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.57",
                                            "spread": "4.14"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "7.03",
                                            "spread": "3.27"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "OTHER_PRE_SPECIFIED",
                    "title": "Trail Making Test - Part A (TMT-A) From Baseline to End of Treatment (3 Weeks), Follow-Up 1 (45 Days Post Treatment) and Follow-Up 2 (90 Days Post Treatment)",
                    "description": "The Trail Making Test- part A (TMT-A) is a assessment of psychomotor speed and is a timed test in which participants must connect a series of numbers randomly placed on a page. Time range is between 0 and 150 seconds, with higher score representing worse performance.",
                    "populationDescription": "The analysis population is Per Protocol, with all participants enrolled and randomized in the clinical trial, and who complete the treatment without major breaches in the study protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "Baseline to End of Treatment (3 weeks), Follow-Up 1 (45 days post treatment) and Follow-Up 2 (90 days post treatment)",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sagramostim (Leukine)",
                            "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Control Group",
                            "description": "Saline placebo comparator: subcutaneous injection"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "20"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "101.50",
                                            "spread": "46.17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "84.85",
                                            "spread": "48.83"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "End of Treatment (3 weeks)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "92.60",
                                            "spread": "45.49"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "79.40",
                                            "spread": "44.56"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 1 (45 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "107.85",
                                            "spread": "45.81"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "84.00",
                                            "spread": "45.64"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Follow-up 2 (90 days post treatment)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "110.35",
                                            "spread": "45.55"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "85.45",
                                            "spread": "48.10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Adverse events were completed over a 20 week period, from Consent to Follow-up 2",
            "description": "Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Sagramostim (Leukine)",
                    "description": "250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 21,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 21,
                    "otherNumAffected": 19,
                    "otherNumAtRisk": 21
                },
                {
                    "id": "EG001",
                    "title": "Control Group",
                    "description": "Saline placebo comparator: subcutaneous injection",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 23,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 23,
                    "otherNumAffected": 20,
                    "otherNumAtRisk": 23
                }
            ],
            "seriousEvents": [
                {
                    "term": "Myocardial Infarction",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 23
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Fatigue",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Injection site reaction",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Rash",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Pain/Myalgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Headache, Benign NOS",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 8,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Upper Respiratory infection",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 23
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "limitationsAndCaveats": {
                "description": "The main weakness is the small sample size of the study."
            },
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "John O'Shaughnessy, MS, Clinical Research Services Principal Professional",
                "organization": "University of Colorado Denver | Anschutz Medical Campus",
                "email": "john.oshaughnessy@cuanschutz.edu",
                "phone": "3037247924"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "Leukine (sargramostim; recombinant human granulocyte\u2013macrophage colony\u2011stimulating factor, GM\u2011CSF)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is Leukine (sargramostim), a recombinant human GM\u2011CSF \u2014 a biologic approved for hematologic/bone\u2011marrow uses (e.g., neutrophil recovery, mobilization of progenitor cells). The trial description states it will be tested for tolerability in AD patients and \u201cpotentially to improve their memory,\u201d indicating the primary intended effect is cognitive improvement rather than a named amyloid\u2011 or tau\u2011directed mechanism. \ue200cite\ue202turn0search2\ue202turn0search5\ue201",
        "Act: Key extracted details \u2014 drug: sargramostim (Leukine); trial title: Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte\u2011Macrophage Colony\u2011Stimulating Factor (Leukine\u00ae) in the Treatment of Alzheimer's Disease; primary aims: safety/tolerability and potential improvement in memory/cognition. Clinical work in humans and preclinical models has tested GM\u2011CSF (sargramostim/G\u2011CSF) for safety and cognitive endpoints in AD and reported cognitive score improvements and biomarker changes. \ue200cite\ue202turn0search3\ue202turn0search1\ue202turn0search6\ue201",
        "Reflect: Classification rationale \u2014 although sargramostim is a biologic, it is being used here to modulate the innate immune system with the goal of improving cognition (memory) rather than as a targeted anti\u2011amyloid or anti\u2011tau monoclonal antibody that explicitly binds pathological aggregates. Therefore, according to the provided category definitions, this trial best fits the \"cognitive enhancer\" category. Note: there is some ambiguity because GM\u2011CSF/related growth factors have shown reductions in amyloid burden in animal studies (a potential disease\u2011modifying signal), but the trial description you provided emphasizes tolerability and memory improvement as endpoints, which aligns more closely with the cognitive enhancer category. \ue200cite\ue202turn0search3\ue202turn0search6\ue201",
        "Web search results / supporting sources summary: (1) Leukine (sargramostim) product/indication information (approved for hematologic/bone\u2011marrow uses). \ue200cite\ue202turn0search2\ue202turn0search5\ue201; (2) Pilot and early human studies of G\u2011CSF/GM\u2011CSF in AD reporting tolerability and cognitive assessments. \ue200cite\ue202turn0search1\ue201; (3) A randomized, double\u2011blind, placebo\u2011controlled trial of sargramostim in mild\u2011to\u2011moderate AD reporting MMSE improvement and biomarker changes (safety/efficacy signals). \ue200cite\ue202turn0search3\ue201; (4) Preclinical animal studies showing G\u2011CSF/GM\u2011CSF reduced amyloid burden and improved cognition in AD models. \ue200cite\ue202turn0search6\ue202turn0search4\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: Sargramostim (Leukine) is a recombinant human granulocyte\u2013macrophage colony\u2011stimulating factor (GM\u2011CSF) that acts on the innate immune system (stimulates granulocyte/macrophage lineage cells and modulates microglial/immune activity). The clinical trial description emphasizes use of GM\u2011CSF to modulate immune responses with the aim of improving cognition rather than an explicit amyloid\u2011 or tau\u2011binding mechanism; this mechanism aligns best with CADRO category F) Inflammation. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act: Extracted details \u2014 drug: sargramostim (Leukine; recombinant human GM\u2011CSF); intervention goal in the trial: safety/tolerability and improvement in memory/cognition in AD patients. GM\u2011CSF is a cytokine/growth factor that modulates innate immunity and has been used clinically for hematologic indications; prior human pilot RCTs of sargramostim in AD reported cognitive score improvements and changes in inflammatory/neuronal biomarkers, consistent with an immune\u2011modulating/inflammation\u2011directed mechanism. Based on these facts, assign category F) Inflammation. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Confirming the fit \u2014 although GM\u2011CSF is a growth factor biologically and some preclinical work shows reductions in amyloid and broader neuroprotective effects (which could suggest overlap with Growth Factors or Proteostasis categories), the proximate mechanism in the trial is modulation of the innate immune system (microglial recruitment/activation, cytokine effects) to alter disease biology or cognition. Under CADRO the most specific and direct match is F) Inflammation rather than L) Growth Factors, because the therapeutic intent and primary mechanism described are immune/inflammatory modulation. If the trial had been explicitly framed as a neurotrophic/growth\u2011factor replacement, L could be considered, or if multiple distinct mechanisms were targeted, R) Multi\u2011target would apply. \ue200cite\ue202turn1search0\ue202turn1search2\ue201",
        "Web search results / supporting sources (summary): (1) Product and mechanism: Leukine (sargramostim) prescribing information and corporate product pages describing sargramostim as recombinant human GM\u2011CSF that stimulates granulocyte/macrophage lineages and modulates innate immunity. \ue200cite\ue202turn0search1\ue202turn0search0\ue201; (2) Human trial data: A randomized, double\u2011blind, placebo\u2011controlled pilot trial of sargramostim in mild\u2011to\u2011moderate AD reported MMSE improvement and changes in plasma biomarkers (innate immune markers, A\u03b2 and tau\u2011related measures), supporting an immune\u2011modulating therapeutic effect. \ue200cite\ue202turn0search2\ue201; (3) Preclinical evidence: Multiple animal studies show GM\u2011CSF administration reduced brain amyloid burden, altered microglial activity, improved cognition, and in some models reduced tau pathology \u2014 indicating pleiotropic effects but with a clear immune/inflammation axis. \ue200cite\ue202turn1search0\ue202turn1search2\ue201"
    ]
}